loadpatents
Patent applications and USPTO patent grants for TRILLIUM THERAPEUTICS INC.The latest application filed is for "biomarkers for cd47 blockade therapy".
Patent | Date |
---|---|
Biomarkers For Cd47 Blockade Therapy App 20220289821 - Johnson; Lisa Danae Schultz ;   et al. | 2022-09-15 |
Cd47 Blockade With Parp Inhibition For Disease Treatment App 20210315864 - Johnson; Lisa Danae Schultz ;   et al. | 2021-10-14 |
Cd47 Blockade With Radiation Therapy App 20210244816 - Cui; Lei ;   et al. | 2021-08-12 |
Treatment Of Cd47+ Disease Cells With Sirp Alpha-fc Fusions App 20210206829 - Uger; Robert Adam ;   et al. | 2021-07-08 |
Cd47 Blockade Therapy With Cd38 Antibody App 20210040224 - LIN; Gloria Hoi Ying ;   et al. | 2021-02-11 |
Improvements In Cd47 Blockade Therapy By Egfr Antibody App 20210040219 - LIN; Gloria Hoi Ying ;   et al. | 2021-02-11 |
Treatment of CD47+ disease cells with SIRP.alpha.-Fc fusions Grant 10,906,954 - Uger , et al. February 2, 2 | 2021-02-02 |
Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins Grant 10,696,670 - Slassi , et al. June 30, 2 | 2020-06-30 |
Fluorinated Amide Derivatives And Their Uses As Therapeutic Agents App 20200181067 - Slassi; Abdelmalik | 2020-06-11 |
Cd47 Blockade Therapy App 20200157179 - LIN; Gloria Hoi Ying ;   et al. | 2020-05-21 |
Fluorinated amide derivatives and their uses as therapeutic agents Grant 10,604,476 - Slassi | 2020-03-31 |
Heteroaromatic-fused Imidazolyl Amides, Compositions And Uses Thereof As Sting Agonists App 20200031825 - Slassi; Abdelmalik ;   et al. | 2020-01-30 |
Heterocycle Derivatives And Their Use For The Treatment Of Cns Disorders App 20190367466 - Slassi; Abdelmalik | 2019-12-05 |
Heterocycle derivatives and their use for the treatment of CNS disorders Grant 10,428,030 - Slassi October 1, 2 | 2019-10-01 |
Improvements In Cd47 Blockade Therapy By Hdac Inhibitors App 20190269756 - Linderoth; Emma ;   et al. | 2019-09-05 |
Enhancement Of Cd47 Blockade Therapy By Proteasome Inhibitors App 20190255082 - Linderoth; Emma ;   et al. | 2019-08-22 |
Fluorinated Imidazo[4,5-c]quinoline Derivatives As Inhibitors Of Bromodomain Containing Proteins App 20190202825 - Slassi; Abdelmalik ;   et al. | 2019-07-04 |
Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins Grant 10,259,809 - Slassi , et al. | 2019-04-16 |
Macrophage Stimulation In Cd47 Blockade Therapy App 20190091290 - Lin; Gloria Hoi Ying ;   et al. | 2019-03-28 |
Novel Fluorinated Quinazoline Derivatives As Egfr Inhibitors App 20190016689 - Slassi; Abdelmalik ;   et al. | 2019-01-17 |
Fluorinated Amide Derivatives And Their Uses As Therapeutic Agents App 20180334425 - SLASSI; Abdelmalik | 2018-11-22 |
Heterocycle Derivatives And Their Use For The Treatment Of Cns Disorders App 20180312480 - Slassi; Abdelmalik | 2018-11-01 |
Treatment of CD47+ Disease Cells with SIRP Alpha-FC Fusions App 20180312563 - Uger; Robert Adam ;   et al. | 2018-11-01 |
Treatment of CD47+ disease cells with SIRP alpha-Fc fusions Grant 9,969,789 - Uger , et al. May 15, 2 | 2018-05-15 |
Novel Fluorinated Derivatives As Egfr Inhibitors Useful For Treating Cancers App 20180050993 - Slassi; Abdelmalik ;   et al. | 2018-02-22 |
Process For The Synthesis Of Difluoromethyl Ether-based Compounds App 20180016227 - Slassi; Abdelmalik ;   et al. | 2018-01-18 |
Fluorinated Imidazo[4,5-c]quinoline Derivatives As Inhibitors Of Bromodomain Containing Proteins App 20180016271 - Slassi; Abdelmalik ;   et al. | 2018-01-18 |
Fluorinated Epoxyketone-based Compounds And Uses Thereof As Proteasome Inhibitors App 20160347792 - Slassi; Abdelmalik ;   et al. | 2016-12-01 |
Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors Grant 9,441,012 - Slassi , et al. September 13, 2 | 2016-09-13 |
Treatment of CD47+ Disease Cells with SIRP Alpha-FC Fusions App 20150329616 - Uger; Robert Adam ;   et al. | 2015-11-19 |
Multimeric Fc receptor polypeptides Grant 8,729,247 - Hogarth , et al. May 20, 2 | 2014-05-20 |
HB-EGF Composition and Use Thereof to Treat a Condition Associated With Enhanced Urothelium Permeability App 20130102532 - Uger; Robert ;   et al. | 2013-04-25 |
Assay for Soluble CD200 App 20120264145 - Gorczynski; Reginald M. ;   et al. | 2012-10-18 |
Assay for soluble CD200 Grant 8,206,897 - Gorczynski , et al. June 26, 2 | 2012-06-26 |
Methods of treating cancer by administering antibodies to CD200 Grant 8,187,598 - Gorczynski , et al. May 29, 2 | 2012-05-29 |
Methods And Compositions For Modulating Immunity App 20110206668 - GORCZYNSKI; REGINALD M. ;   et al. | 2011-08-25 |
Methods Of Treating Cancer By Administering Antibodies To Cd200 App 20110129466 - GORCZYNSKI; REGINALD M. ;   et al. | 2011-06-02 |
Fc receptor modulating compounds and compositions Grant 7,910,770 - Hogarth , et al. March 22, 2 | 2011-03-22 |
Methods and compositions for modulating immunity Grant 7,902,151 - Gorczynski , et al. March 8, 2 | 2011-03-08 |
Methods of treating cancer by administering antibodies to CD200 Grant 7,887,798 - Gorczynski , et al. February 15, 2 | 2011-02-15 |
Methods and Compositions For Modulating Immunity App 20090232825 - GORCZYNSKI; REGINALD M. ;   et al. | 2009-09-17 |
Methods and compositions for modulating immunity Grant 7,553,811 - Gorczynski , et al. June 30, 2 | 2009-06-30 |
Methods of Treating Cancer by Administering Antibodies to CD200 App 20090053222 - GORCZYNSKI; REGINALD M. ;   et al. | 2009-02-26 |
Methods of treating cancer by administering antibodies to CD200 Grant 7,452,536 - Gorczynski , et al. November 18, 2 | 2008-11-18 |
Fc Receptor Modulating Compounds and Compositions App 20080146632 - Hogarth; Mark Phillip ;   et al. | 2008-06-19 |
CD200 receptors Grant 7,368,535 - Gorczynski , et al. May 6, 2 | 2008-05-06 |
Fc.gamma.RIIa transgenic animal model for autoimmune disease Grant 7,351,875 - Hogarth , et al. April 1, 2 | 2008-04-01 |
Fc receptor modulating compounds and compositions Grant 7,332,631 - Hogarth , et al. February 19, 2 | 2008-02-19 |
Multimeric Fc Receptor Polypeptides App 20080008700 - Hogarth; Phillip Mark ;   et al. | 2008-01-10 |
MD-1 inhibitors as immune suppressants Grant 7,291,330 - Gorczynski , et al. November 6, 2 | 2007-11-06 |
Methods and compositions for modulating tumor growth Grant 7,238,352 - Gorczynski , et al. July 3, 2 | 2007-07-03 |
Methods of treating allergy by administering a CD200 protein Grant 7,223,729 - Gorczynski May 29, 2 | 2007-05-29 |
Truncated CD200 Grant 7,205,386 - Gorczynski April 17, 2 | 2007-04-17 |
Transgenic animal containing CD200 and uses therefor Grant 7,196,243 - Gorczynski March 27, 2 | 2007-03-27 |
Methods and compositions for modulating autoimmunity Grant 6,984,625 - Gorczynski January 10, 2 | 2006-01-10 |
Methods of inhibiting immune response suppression by administering antibodies to OX-2 Grant 6,955,811 - Gorczynski , et al. October 18, 2 | 2005-10-18 |
Compositions comprising antibodies to human FgI2 App 20050169913 - Levy, Gary ;   et al. | 2005-08-04 |
Methods and compositions for modulating immunity App 20050048069 - Gorczynski, Reginald M. ;   et al. | 2005-03-03 |
Treatment of chronic human viral hepatitis App 20050042226 - Levy, Gary ;   et al. | 2005-02-24 |
Methods of modulating immune coagulation Grant 6,805,863 - Levy October 19, 2 | 2004-10-19 |
Use of OX-2 to inhibit fetal loss Grant 6,749,854 - Gorczynski , et al. June 15, 2 | 2004-06-15 |
Use of OX-2 to suppress an immune response Grant 6,652,858 - Gorczynski , et al. November 25, 2 | 2003-11-25 |
Fgl-2 knockout mice Grant 6,642,433 - Levy , et al. November 4, 2 | 2003-11-04 |
SEC | 0001616212 | Trillium Therapeutics Inc. of ONTARIO, CANADA |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.